https://www.yiliao.com/index.php?action=history&feed=atom&title=Zongertinib
Zongertinib - 版本历史
2026-04-18T19:36:50Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Zongertinib&diff=317414&oldid=prev
223.160.136.180：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-03-23T07:11:08Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Zongertinib]]</strong>，研发代码为<strong>[[BI 1810631]]</strong>，是一种口服、高选择性、共价结合的<strong>[[HER2酪氨酸激酶抑制剂]] (TKI)</strong>。作为新一代HER2靶向药物，Zongertinib的设计重点在于对<strong>[[HER2]] (ERBB2)</strong> 的高度选择性，尤其是针对<strong>[[HER2外显子20插入突变]]</strong>。与传统的泛HER受体抑制剂不同，它能有效规避对野生型[[EGFR]]的抑制，从而显著降低皮疹和腹泻等副作用。目前，该药物在[[非小细胞肺癌]] (NSCLC) 的精准治疗领域，尤其是Beamion系列临床研究中展现了卓越的抗肿瘤活性。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #f0f9ff 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Zongertinib (BI 1810631)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Selective HER2 TKI · 核心参数</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">Structure:<br>HER2-Selective Covalent Inhibitor</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[HER2]] (ERBB2)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ERBB2</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P04626</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2623192-31-0</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">小分子不可逆TKI</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">主要适应症</th><br />
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">HER2突变型NSCLC</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：高选择性共价封锁</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
Zongertinib的作用机制体现了现代药物化学对激酶结构域精准识别的最高要求：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>不可逆共价结合：</strong> Zongertinib通过与HER2激酶结构域[[ATP]]结合口袋中的特定半胱氨酸残基形成共价键，持久抑制受体自磷酸化及下游信号传导。</li><br />
<li style="margin-bottom: 12px;"><strong>外显子20插入覆盖：</strong> 该药特别针对[[HER2外显子20插入突变]]（如YVMA插入）的空间构象进行了优化，在突变体蛋白上的结合力远强于野生型。</li><br />
<li style="margin-bottom: 12px;"><strong>EGFR 豁免效应：</strong> 通过结构修饰，Zongertinib对野生型[[EGFR]]的抑制作用极弱，这使其在达到治疗浓度的同时，能够有效避免皮疹、粘膜炎等由EGFR失活引起的剂量限制性毒性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床数据矩阵</h2><br />
<div style="overflow-x: auto; margin: 30px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">研究名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">研究人群</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键临床终点 (数据摘要)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Beamion Lung-1]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2突变型经治或初治NSCLC。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在TKI初治人群中，客观缓解率(ORR)显著，安全性良好。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Phase Ia/Ib探索</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">晚期实体瘤（含HER2扩增/突变）。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">确立了推荐临床剂量(RP2D)，展现出泛癌种HER2抑制潜力。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用策略与前景</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>针对性检测：</strong> 应用Zongertinib前，需通过高通量测序（[[NGS]]）明确HER2突变类型，尤其是确认是否存在外显子20插入突变。</li><br />
<li style="margin-bottom: 12px;"><strong>毒性分级管理：</strong> 尽管其对EGFR影响较小，但仍需监测潜在的间质性肺病（[[ILD]]）及肝酶升高。早期识别并进行剂量调整是维持长期获益的关键。</li><br />
<li style="margin-bottom: 12px;"><strong>序贯治疗思考：</strong> 在[[德曲替珠单抗]] (T-DXd) 等抗体偶联药物（ADC）耐药后，Zongertinib作为小分子TKI可提供差异化的耐药克服机制。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;"><br />
<li style="margin-bottom: 8px;">[[HER2 exon 20 insertion]]</li><br />
<li style="margin-bottom: 8px;">[[EGFR-sparing]]</li><br />
<li style="margin-bottom: 8px;">[[不可逆抑制剂]]</li><br />
<li style="margin-bottom: 8px;">[[Beamion研究]]</li><br />
<li style="margin-bottom: 8px;">[[德曲替珠单抗]]</li><br />
<li style="margin-bottom: 8px;">[[吡咯替尼]]</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Heymach J, et al. (2023).</strong> <em>Zongertinib (BI 1810631) in patients with HER2-mutant NSCLC: Primary analysis of the Beamion Lung-1 trial.</em> <strong>[[World Conference on Lung Cancer]] (WCLC)</strong>.<br><br />
<span style="color: #475569;">[学术点评]：该研究揭示了Zongertinib在特定突变亚型中的高响应率，尤其强调了其优异的治疗窗口。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Ruiter G, et al. (2023).</strong> <em>BI 1810631, a highly selective HER2-TKI for patients with HER2-mutant cancers.</em> <strong>[[Annals of Oncology]]</strong>. [Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：通过结构生物学手段实现的“EGFR豁免”特性，使得Zongertinib在联合用药方面具有更强的灵活性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Zongertinib (BI 1810631) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[ERBB2]]•[[ATP-binding domain]]•[[MAPK/ERK通路]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">对比/联用</td><br />
<td style="padding: 10px 15px; color: #334155;">[[德曲替珠单抗]]•[[莫博替尼]]•[[吡咯替尼]]•[[波奇替尼]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Boehringer Ingelheim]]•[[FDA]]•[[NMPA]]•[[IASLC]]</td><br />
</tr><br />
<tr><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克服ADC耐药]]•[[血脑屏障穿透力研究]]•[[与免疫治疗联合]]•[[一线治疗探索]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.180